Key result
The hypothesis that the reversible nature of platelet binding causing TRALI syndrome explains dyspnea after ticagrelor and elinogrel remains unproven.
Answers are grounded in this paper and cite their sources.
This editorial discusses the unproven hypothesis that reversible platelet binding causing TRALI syndrome may explain dyspnea after ticagrelor and elinogrel.
'Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel' – a hypothesis that remains unproven - Editorial on Serebruany: ‘Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel’ (Thromb Haemost 2012; 108.6)
No takes yet. Share an insight, caveat, or question.
Karsten Schrör (2012) conducted an editorial in Dyspnea after ticagrelor and elinogrel. Ticagrelor and elinogrel was evaluated. The hypothesis that the reversible nature of platelet binding causing TRALI syndrome explains dyspnea after ticagrelor and elinogrel remains unproven.
Synapse has enriched 10 related papers. Consider them for comparative context: